KCA
PFE icon

Karn Couzens & Associates’s Pfizer PFE Stock Holding History

Karn Couzens & Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$207K Hold
4,000
– – 0.13% 88
2021
Q4 		$236K Buy
+4,000
New +$198K 0.16% 74

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Karn Couzens & Associates's PFE Position: Q1 2022 in Review

Karn Couzens & Associates held its Pfizer (PFE) position steady in Q1 2022 at 4,000 shares worth $207K. The position accounts for 0.13% of the portfolio, ranked #88.

Karn Couzens & Associates first reported a position in PFE in Q4 2021 and has held it in 2 quarters since. The position peaked at $236K in Q4 2021. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

  • Karn Couzens & Associates held 4,000 shares of Pfizer worth $207K as of Q1 2022.
  • Karn Couzens & Associates left its Pfizer share count unchanged in Q1 2022.
  • Pfizer made up 0.13% of Karn Couzens & Associates's portfolio in Q1 2022, its #88 holding.
  • Karn Couzens & Associates first reported a position in Pfizer in Q4 2021 and has held it in 2 quarters since.
  • Karn Couzens & Associates's Pfizer position peaked at $236K in Q4 2021.
  • 3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on Karn Couzens & Associates's 13F filing for Q1 2022, filed 19 Apr 2022.